The Melanotan-1 Lineage: How an Academic Peptide Became an Approved Drug in the EU

This article describes published laboratory science for educational purposes. It makes no claims about use in people.

Melanotan-1 is the research name for a modified alpha-MSH analog. The same sequence, under the name afamelanotide, followed a long regulatory road.

The beginnings

Victor Hruby’s group at the University of Arizona designed the analog in the 1980s, swapping methionine for norleucine and L-phenylalanine for its mirror image, D-phenylalanine, to make a more stable, more potent compound than natural alpha-MSH.

Licensing and trials

The compound was developed commercially, and after clinical trials, it was approved by the European Medicines Agency in 2014 for a rare condition called erythropoietic protoporphyria. That is a prescription medicine under medical supervision, a very different thing from any research chemical.

What the story teaches researchers

• A sequence can go from a bench idea to a regulated drug, but only through years of controlled studies.
• Research-grade material is not the same as a licensed medicine.

The Melanotan-1 10mg listing on our site is for laboratory use only. Keep reading for the receptor side.

Explore Lucid Aminos

• Shop all research compounds
• Read the lab reports (COA)
• Frequently asked questions
• Partner program
• About Lucid Aminos
• Contact us

For laboratory research use only. Not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any condition. This article is educational and is not medical advice.